Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients

Experimental and Molecular Medicine

Volumn 41, Issue 2, 2009, Pages 67-76

  Cho, Kyung Hyun ^a   Shin, Dong Gu ^b   Baek, Suk Hwan ^a   Kim, Jae Ryong ^a  

^a Yeungnam University   (South Korea)

^b Yeungnam University Hospital   (South Korea)

Author keywords

Angina pectoris; Biological markers; Cholesteryl ester transfer protein; Inflammation; Interleukin 6; Lipoproteins; Myocardial infarction

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; COPPER; GLUCOSE; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; CETP PROTEIN, HUMAN; LIPID;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HEART INFARCTION; HUMAN; KOREA; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; STABLE ANGINA PECTORIS; AGED; ANGINA PECTORIS; BLOOD; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION;

ANGINA;

AGED; ANGINA PECTORIS; APOLIPOPROTEIN C-III; CHOLESTEROL ESTER TRANSFER PROTEINS; COPPER; HUMANS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; TRIGLYCERIDES;

EID: 63849343525     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2009.41.2.009     Document Type: Article

References (31)

1. Asia pacific cohort studies collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the asia-pacific region. Circulation 2004;110:2678-2686
2. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988;260:1917-1921
3. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004;109:837-842 (Pubitemid 38252734)
4. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996;239:70-76
5. 2. Bioorg Med Chem Lett 2000;10:2557-2561
6. Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PWF, Shaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187-195
7. Cho KH, Lee JY, Choi MS, Cho JM, Lim JS, Park YB. A peptide from hog plasma that inhibits human cholesteryl ester transfer protein. Biochim Biophys Acta 1998;1391:133-144 (Pubitemid 28189628)
8. Cho KH, Park SH, Han JM, Kim HC, Choi YK, Choi I. ApoA-I mutants V156K and R173C promote anti-inflammatory function and antioxidant activities. Eur J Clin Invest 2006;36:875-882
9. Cho KH, Park JE, Kim YO, Choi I, Kim JJ, Kim JR. The function, composition, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome. Clin Biochem 2008;41:56-64 (Pubitemid 350216831)
10. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138 (Pubitemid 14201166)
11. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103:1955-1960 (Pubitemid 32322222)
12. Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Famillial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-2033
13. Han JM, Jeong TS, Lee WS, Choi I, Cho KH. Structural and functional properties of V156K and A158E mutants of apolipoprotein A-I in the lipid-free and lipid-bound states. J Lipid Res 2005;46:589-596 (Pubitemid 43109795)
14. Hartford M, Wiklund O, Hullten LM, Persson A, Karlsson T, Herlitz J, Caidahl K. C reactive protein, interleukin-6, secretory phospholipase A group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med 2007;262:526-536 (Pubitemid 47620509)
15. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level. J Cardiovasc Risk 1996;3:213-219
16. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, Katus H. It's time for a change to a troponin standard. Circulation 2000;102:1216-1220
17. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine, 16th Ed, McGraw-Hill, 2005, p.1444
18. Libby P. Fat fuels the flame triglyceride-rich lipoproteins and arterial inflammation. Circulation 2007;100:299-301 (Pubitemid 46272401)
19. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978;87:206-210 (Pubitemid 9050428)
20. McBride PE. Triglycerides and risk for coronary heart disease. J Am Med Assoc 2007;298:336-338 (Pubitemid 47080491)
21. Meuwese MC, Stroes ESG, Hazen SL, Van Miert JN, Keivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJP, Khaw, KT, Boekholdt M. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals. J Am Coll Cardiol 2007;50:159-165
22. Packard CJ, O'Reilly DSJ, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GDO. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-1155
23. Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, Applegate WB. Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med 1999;159:237-245 (Pubitemid 29075643)
24. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K. Heart disease and stroke statistics-2007 Update. Circulation 2007;115e:e69-e171
25. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, aolipoprotein B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events trial. Circulation 2000;102:1886-1892
26. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006;21:322-328 (Pubitemid 44315065)
27. Suzuki H, Kusuyama T, Sato R, Yokota Y, Tsunoda F, Sato T, Shoji M, Iso Y, Koba S, Katagiri T. Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction. Eur J Clin Invest 2008;38:166-173
28. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M. Universal definition of myocardial infarction. Circulation 2007;116:2634-2653 (Pubitemid 350182388)
29. Tsimikas S, Willerson JT, Ridker, PM. C-Reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47:C19-31
30. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 2006;95:511-518
31. Walldius G, Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I-new risk factors and targets for therapy. Nutr Metab Cardiovasc Dis 2007;17:565-571 (Pubitemid 47302307)